首页>外文期刊>医学、药学、卫生>药学>GaBi journal.

GaBi journal.

中文名称：GaBi杂志》。

ISSN：2033-6403
出版周期：Quarterly

发文量：344

期刊论文

热门论文

年度选择

更多>>

全选（0）

1.IAPO launched the Patient-Centred Healthcare Indicators Review

机译：IAPO推出了以患者为中心的医疗保健指标审查
- 作者：Yasemin Dil
- 期刊名称：《GaBi journal.》 | 2013年第1期
2.Interchangeability of biosimilars in the US and around the world

机译：美国和世界各地生物仿制性的互换性
- 作者：GaBI Journal Editor
- 期刊名称：《GaBi journal.》 | 2017年第2期
3.Overview of the patent expiry of (non-)tyrosine kinase inhibitors approved for clinical use in the EU and the US

机译：欧盟和美国临床用途（非）酪氨酸激酶抑制剂的专利到期概述
- 作者：Associate Professor Martine Lamfers PhD;?Professor Arnold G Vulto PharmD PhD FCP;?Professor Sieger Leenstra MD PhD?
- 期刊名称：《GaBi journal.》 | 2017年第2期
4.Assessing biosimilarity using the method of generalized pivotal quantities

机译：使用广义枢轴量的方法评估生物纤加性
- 作者：1 Shih-Ting Chiu MSc;et al.
- 期刊名称：《GaBi journal.》 | 2013年第3期
5.Global challenges in the manufacture, regulation and international harmonization of GMP and quality standards for biopharmaceuticals

机译：全球挑战在制造，监管和国际GMP和生物制药质量标准的统一
- 作者：Sia Chong Hock;Sia Ming Kian;Chan Lai Wah
- 期刊名称：《GaBi journal.》 | 2020年第2期
- ASEANbiopharmaceutical manufacturingbiopharmaceuticalsgood manufacturing practiceharmonizationregulatory guidelines;
6.Poor traceability of biologicals in UK ADR reporting indicates the need for improvements to ensure patient safety

机译：在英国ADR报告中的生物学可追溯性不佳表明需要改进以确保患者安全
- 作者：Kevin Klein
- 期刊名称：《GaBi journal.》 | 2020年第2期
7.Current trends for biosimilars in the Latin American market

机译：拉丁美洲市场中生物仿制性的当前趋势
- 作者：Esteban Ortiz-Prado;Jorge Ponce-Zea;Jorge E Vasconez;Diana Castillo;Diana C Checa-Jaramillo;Nathalia Rodríguez-Burneo;Felipe Andrade;Damaris P Intriago-Baldeón;Claudio Galarza-Maldonado
- 期刊名称：《GaBi journal.》 | 2020年第2期
- biologicalsbiopharmaceuticalsbiosimilarsLatin America;
8.Policy recommendations for a sustainable biosimilars market: lessons from Europe

机译：可持续生物仿制性市场的政策建议：欧洲的课程
- 作者：Philip J Schneider;Michael S Reilly
- 期刊名称：《GaBi journal.》 | 2020年第2期
- biologicals/biosimilarscompetitionpatientsprocurementsubstitutionsustainability;
9.Clinical trials for trastuzumab biosimilars

机译：Trastuzumab BioSimilars的临床试验
- 期刊名称：《GaBi journal.》 | 2020年第2期
- biosimilarclinical trialstrastuzumab;
10.Importance of the determination of the higher order structure in the in-use stability studies of biopharmaceuticals

机译：生物制药中使用稳定性研究中较高阶结构的确定性的重要性
- 作者：Alain Astier
- 期刊名称：《GaBi journal.》 | 2020年第2期
- analysisbiosimilarproteinspectroscopystructure;
11.What to look forward to in GaBI Journal, 2020, Issue 2

机译：什么期待在Gabi Journal，2020年期间，第2期
- 作者：Philip D Walson
- 期刊名称：《GaBi journal.》 | 2020年第2期
12.Biosimilars markets: US and EU compared

机译：BioSimilars市场：美国和欧盟比较
- 期刊名称：《GaBi journal.》 | 2020年第2期
- biosimilarEMAregulationUS Food and Drug Administration (FDA);
13.Biosimilars – status in July 2020 in 16 countries

机译：BioSimilars - 1920年7月在16个国家的状态
- 作者：Hye-Na Kang;Robin Thorpe;Ivana Knezevic;Daehyun Baek;Parichard Chirachanakul;Hui Ming Chua;Dina Dalili;Freddie Foo;Kai Gao;Suna Habahbeh;Hugo Hamel;Edwin Nkansah;Maria Savkina;Oleh Semeniuk;Shraddha Srivastava;Jo?o Tavares Neto;Meenu Wadhwa;Teruhide Yamaguchi
- 期刊名称：《GaBi journal.》 | 2021年第1期
- approvalbiosimilarsurveyWHO;
14.Continuous manufacturing versus batch manufacturing: benefits,opportunities and challenges for manufacturers and regulators

机译：连续制造与批量制造：制造商和监管机构的利益，机会和挑战
- 作者：Sia Chong Hock;Teh Kee Siang;Chan Lai Wah
- 期刊名称：《GaBi journal.》 | 2021年第1期
- batch manufacturingchallengescontinuous manufacturingharmonizationopportunityregulatory;
15.An assessment of trends in the Iranian pharmaceutical market following domestic production of selected medications (2007?2017) and new considerations for health policymakers

机译：伊朗医药市场趋势评估在国内生产药物（2007年 - 2017年）和卫生政策制定者的新考虑因素
- 作者：Marzieh Zargaran;Abdol Majid Cheraghali;Fatemeh Soleymani;Rajabali Daroudi;Ali Akbari Sari;Shekoufeh Nikfar
- 期刊名称：《GaBi journal.》 | 2021年第1期
- Domestic productionIranian health policymedicines consumptionpharmaceutical industrypharmaceutical markettrend analysis;
16.Medical journal publication during global stress

机译：全球压力期间医学期刊出版
- 作者：Philip D Walson
- 期刊名称：《GaBi journal.》 | 2020年第4期
17.Pharmaceutical Data Integrity: issues, challenges and proposed solutions for manufacturers and inspectors

机译：制药数据完整性：制造商和检查员的问题，挑战和提出的解决方案
- 作者：Sia Chong Hock;Vernon Tay;Vimal Sachdeva;Chan Lai Wah
- 期刊名称：《GaBi journal.》 | 2020年第4期
- ALCOA-plusaudit trailblockchain technologycomputerized systemcooperationdata integrity;
18.Systematic analysis of injection-site pain and reactions caused by subcutaneous administration of the adalimumab biosimilar FKB327 versus the adalimumab reference product via different delivery methods

机译：通过不同的递送方法对注射部位疼痛和通过皮下施用的药物杀死AdalimalAB的反应产生的系统分析
- 作者：Rieke Alten;Herbert Kellner;Malcolm Boyce;Takuma Yonemura;Takahiro Ito;Mark C Genovese
- 期刊名称：《GaBi journal.》 | 2020年第3期
- adalimumabanti-TNF therapybiosimilarsclinical trialsinjection-site painrheumatoid arthritis;
19.Pelmeg?, a biosimilar pegfilgrastim developed in the context of evolving regulatory guidelines

机译：Pelmeg ?,一个生物冻害的Pegfilgrastim在不断变化的监管指南的背景下发展
- 作者：Karsten Roth;Hendrik Wessels;Josef H?fler;Ulrike Scholz;Dirk Lehnick
- 期刊名称：《GaBi journal.》 | 2020年第3期
- biosimilarfilgrastimNeulasta?pegfilgrastimPelmeg?targeted development;
20.European prescribers’ attitudes and beliefs on biologicals prescribing and automatic substitution

机译：欧洲公务员对生物制定和自动替代的态度和信仰
- 作者：Madelaine Feldman;Michael S Reilly
- 期刊名称：《GaBi journal.》 | 2020年第3期
- biological medicinesbiosimilarEUprescriberssubstitutionsurvey;
21.3rd Colombian educational workshop on regulatory assessment of biosimilars 2019 – Report

机译：第三届哥伦比亚教育研讨会生物仿制性评估2019年 - 报告
- 作者：John-Joseph Borg;Yolanda Elias Gramajo;Andrea Laslop;Robin Thorpe;Jian Wang
- 期刊名称：《GaBi journal.》 | 2020年第3期
- biologicalsbiosimilarsColombiaINVIMA;
22.Local policies on biosimilars: are they designed to optimize use of liberated resources?

机译：BioSimilars的当地政策：他们是否旨在优化利用解放资源？
- 作者：Arianna Bertolani;Claudio Jommi
- 期刊名称：《GaBi journal.》 | 2020年第4期
- biosimilarsItalian national health servicelocal;
23.Is the local tolerance of injectable biosimilars too underestimated?

机译：局部可注射生物仿制性的耐受性太高估计不容吗？
- 作者：Alain Astier
- 期刊名称：《GaBi journal.》 | 2020年第4期
24.A white paper: US biosimilars market on pace with Europe

机译：白皮书：与欧洲的速度上的美国生物仿制性市场
- 作者：Madelaine A Feldman;Michael S Reilly
- 期刊名称：《GaBi journal.》 | 2020年第4期
- biosimilarscompetitionFDAMarket sharesustainabilityUS;
25.Physicochemical stability of the bevacizumab biosimilar, ABP 215, after preparation and storage in intravenous bags

机译：Bevacizumab BioSimilar，ABP 215的物理化学稳定性，在静脉袋中制备和储存后
- 作者：olita Seckute;Ingrid Castellanos;Steven Bane
- 期刊名称：《GaBi journal.》 | 2020年第4期
- ABP 215administrationbevacizumabbiosimilarinfusionstability;
26.Can local policies on biosimilars optimize the use of freed resources – experiences from Italy

机译：BioMimilars的地方政策可以优化利用释放资源的使用 - 意大利的经验
- 作者：Brian Godman;Eleonora Allocati;Evelien Moorkens;Hye-Young Kwon
- 期刊名称：《GaBi journal.》 | 2020年第4期
27.Quality standards for biopharmaceuticals: the importance of good manufacturing practice

机译：生物制药质量标准：良好制造业实践的重要性
- 作者：Elwyn Griffiths
- 期刊名称：《GaBi journal.》 | 2020年第3期
- ASEANbiologicalsbiosimilarsGMPregulatory harmonization;
28.Qualitative survey-based evaluation of operability and convenience for the etanercept biosimilar YLB113 in a unique injection pen in patients with rheumatoid arthritis

机译：基于风湿性关节炎患者独特注射笔中的Etanercept BioSimilar YLB113的定性调查的可操作性和便利性
- 作者：Toshihiko Hibino;Tomohiko Yoshida;Akira Sagawa;Ikuko Masuda;Takaaki Fukuda
- 期刊名称：《GaBi journal.》 | 2020年第3期
- etanerceptinjection penneedle fearrheumatoid arthritisusabilityYLB113;
29.Latest features in GaBI Journal, 2020, Issue 3

机译：Gabi Journal，2020年的最新功能，第3期
- 作者：Philip D Walson
- 期刊名称：《GaBi journal.》 | 2020年第3期
30.A critical review of substitution policy for biosimilars in Canada

机译：加拿大生物仿碎政策替代政策的关键综述
- 作者：Philip J Schneider;Michael S Reilly
- 期刊名称：《GaBi journal.》 | 2021年第3期
- biosimilarsCanadapolicysubstitutionswitching;
31.An IPRP survey of the regulatory requirements for the waiver of in vivo bioequivalence studies of generic medicinal products in certain dosage forms

机译：对某些剂型普通药用产品的豁免豁免的监管要求的IPRP调查
- 作者：Alfredo García Arieta;Clare Rodrigues
- 期刊名称：《GaBi journal.》 | 2021年第3期
32.An overview of the current status of follow-on biologicals in Iran

机译：伊朗后续生物学现状概述
- 作者：Farhang Rezaei;Nassim Anjidani
- 期刊名称：《GaBi journal.》 | 2021年第2期
- biosimilarsBiotechnological therapeuticsfollow-on biologicsIran;
33.Biosimilar epoetin for cancer and chemotherapy-induced anaemia in the US

机译：BioSimilar Epoetin用于癌症和化疗诱导的血症
- 期刊名称：《GaBi journal.》 | 2021年第3期
34.What to look forward to in GaBI Journal, 2021, Issue 2

机译：什么期待在加比期刊，2021年，第2期
- 作者：Philip D Walson
- 期刊名称：《GaBi journal.》 | 2021年第2期
35.Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching

机译：沙特阿拉伯生物仿制物：单中心，开放式案例系列检查incixImab切换
- 作者：Mansour Somaily;Hana Alahmari;Wejdan Abbag;Shahenda Yousif;Nawar Tayfour;Nouf Almushayt;Saleh Alhusayni;Saeed Almajadiah
- 期刊名称：《GaBi journal.》 | 2021年第2期
- Ankylosing spondylitisBechet's diseaseCT-P13infliximabrheumatoid arthritis;
36.Latest features in GaBI Journal, 2021, Issue 3

机译：2021年GABI Journal的最新功能，第3期
- 作者：Philip D Walson
- 期刊名称：《GaBi journal.》 | 2021年第3期
37.Summative usability evaluation of the YLB113 etanercept biosimilar autoinjector via simulation

机译：通过仿真的YLB113 entanercept生物膜自动化器的总结可用性评估
- 作者：Kelly Canham;Claire Newcomb
- 期刊名称：《GaBi journal.》 | 2021年第2期
- autoinjectorbiosimilaretanerceptusabilityYLB113;
38.Variation in the prices of oncology medicines across Europe and the implications for the future

机译：欧洲肿瘤医学价格的变化以及对未来的影响
- 作者：Brian Godman;Steven Simoens;Amanj Kurdi;Gisbert Selke;John Yfantopoulos;Andrew Hill;Jolanta Gulbinovi?;Antony P Martin;Angela Timoney;Dzintars Gotham;Janet Wale;Tomasz Bochenek;Iva Selke Krulichova;Eleonora Allocati;Iris Hoxha;Admir Malaj;Christian Hierlander;Anna Nachtnebel;Wouter Hamelinck;Zornitza Mitkova;Guenka Petrova;Ott Laius;Catherine Sermet;Irene Langner;Roberta Joppi;Arianit Jakupi;Elita Poplavska;Ieva Greiciute-Kuprijanov;Patricia Vella Bonanno;JF (Hans) Piepenbrink;Vincent de Valk;Robert Plisko;Magdalene Wladysiuk;Vanda Markovi?-Pekovi?;Ileana Mardare;Tanja Novakovic;Mark Parker;Jurij Furst;Dominik Tomek;Katarina Banasova;Merce Obach Cortadellas;Corrine Zara;Caridad Pontes;Maria Juhasz-Haverinen;MScPharm;Peter Skiold;Stuart McTaggart;Durhane Wong-Rieger;Stephen Campbell;Ruaraidh Hill
- 期刊名称：《GaBi journal.》 | 2021年第2期
- Cancercross-nationalEuropegenericshealth policypricing;
39.Pharmacokinetics and bioequivalence of generic etoricoxib in healthy volunteers

机译：在健康志愿者中普通etoricoxib的药代动力学和生物等效性
- 作者：Nishalini Harikrishnan;Ka-Liong Tan;Kar Ming Yee;Alia Shaari Ahmad Shukri;Nalla Ramana Reddy;Chuei Wuei Leong
- 期刊名称：《GaBi journal.》 | 2021年第3期
- bioequivalenceCOX-2 inhibitoretoricoxibgenerics;
40.Use of biologicals in dermatology – following the agreed path or going off-piste? A brief report

机译：使用生物学在皮肤科中 - 遵循约定的路径或脱尾？简要介绍
- 作者：Michael Wilcock;Andrew Pothecary
- 期刊名称：《GaBi journal.》 | 2021年第3期
- biologicalsbiosimilarsdermatologypsoriasis;
41.The EU regulatory network and emerging trends – a review of quality, safety and clinical development programmes

机译：欧盟监管网络和新兴趋势 - 对质量，安全和临床发展计划进行审查
- 作者：Marta Zuccarelli;Benjamin Micallef;Mark Cilia;Anthony Serracino-Inglott;John-Joseph Borg
- 期刊名称：《GaBi journal.》 | 2021年第2期
- Biosimilarsclinical development programmesEMAEPARsregulatorysafety;
42.Reasons for patients’ generic drug switching at the pharmacy counter: a pilot study

机译：药房柜台患者通用药物切换的原因：试验研究
- 作者：Pieter J Glerum;Mert Hayta;David M Burger;Cees Neef;Marcel L Bouvy;Marc Maliepaard
- 期刊名称：《GaBi journal.》 | 2021年第3期
- Brand-name drugsdrug switchinggeneric drugsgenerics substitutioninterchangeabilitypharmacy practice;
43.Repurposing non-oncology drugs for cancer treatment

机译：修复非肿瘤药物用于癌症治疗
- 作者：Alice Rolandini Jensen
- 期刊名称：《GaBi journal.》 | 2021年第2期
44.Microbiological, scientific and regulatory perspectives of hand sanitizers

机译：手动消毒剂的微生物，科学和监管角度
- 作者：Sia Chong Hock;Tan Ying Ting;Chan Lai Wah
- 期刊名称：《GaBi journal.》 | 2021年第3期
- Effectivenesshand sanitizersmythsregulatory frameworksafetystandards;
45.Biosimilarity is not a transitive property: implication for interchangeability, naming and pharmacovigilance

机译：Biosimilarity is not a transitive property: implication for interchangeability, naming and pharmacovigilance
- 作者：Pablo Matar
- 期刊名称：《GaBi journal.》 | 2022年第1期
- Divergence;
- drift;
- evolution;
- interchangeability;
- pharmacovigilance;
- variability;
46.What to look forward to in GaBI Journal, 2022, Issue 2

机译：What to look forward to in GaBI Journal, 2022, Issue 2
- 作者：Philip D Walson
- 期刊名称：《GaBi journal.》 | 2022年第2期
47.Challenges in the manufacture, storage, distribution and regulation of traditional and novel vaccines

机译：Challenges in the manufacture, storage, distribution and regulation of traditional and novel vaccines
- 作者：Sia Chong Hock;Adelia Pheh;Vimal SachdevaChan Lai Wa
- 期刊名称：《GaBi journal.》 | 2022年第1期
- Challenges;
- COVID-19 vaccines;
- harmonization;
- manufacturing;
- regulation;
- traditional vaccines;
48.The importance of trust

机译：The importance of trust
- 作者：Philip D Walson
- 期刊名称：《GaBi journal.》 | 2022年第3期
49.Manufacture and regulation of cell, tissue and gene therapy products: global perspectives, challenges and next steps

机译：Manufacture and regulation of cell, tissue and gene therapy products: global perspectives, challenges and next steps
- 作者：Sia Chong Hock;Christine Koh;Chan Lai Wah
- 期刊名称：《GaBi journal.》 | 2022年第2期
- Cell;
- good manufacturing practice;
- quality control;
- regulatory framework;
- tissue and gene therapy products;
50.No need for systematic switch studies to demonstrate interchangeability of biosimilars

机译：No need for systematic switch studies to demonstrate interchangeability of biosimilars
- 作者：Pekka Kurki
- 期刊名称：《GaBi journal.》 | 2022年第1期
- Biosimilars;
- immunogenicity;
- interchangeability;
- switch studies;
51.Structural characterization methods forbiosimilars: fit-for-purpose, qualified or validated - Quality considerations for analytical methods

机译：Structural characterization methods forbiosimilars: fit-for-purpose, qualified or validated - Quality considerations for analytical methods
- 作者：Richard L Easton
- 期刊名称：《GaBi journal.》 | 2022年第1期
- analytical development;
- mass spectrometry;
- process related impurities;
- structural characterization;
52.A case study of AstraZeneca's omeprazole/ esomeprazole chiral switch strategy

机译：A case study of AstraZeneca's omeprazole/ esomeprazole chiral switch strategy
- 作者：Federico J Pineiro;Fernez Argüelles Rogelio Aiberto
- 期刊名称：《GaBi journal.》 | 2022年第2期
- AstraZeneca;
- Big Pharma;
- biosimilars;
- chiral switch;
- esomeprazol;
- generics;
53.Long-acting insulin analogues. Drug selection by means of the System of Objectified Judgement Analysis (SOJA)

机译：Long-acting insulin analogues. Drug selection by means of the System of Objectified Judgement Analysis (SOJA)
- 作者：Robert Janknegt;Marloes Dankers
- 期刊名称：《GaBi journal.》 | 2022年第1期
- Degludec;
- detemir;
- diabetes mellitus;
- glargine;
- long-acting insulin analogues;
- NPH insulin;
54.Biotherapeutic products in the European Pharmacopoeia: have all challenges been tackled?

机译：Biotherapeutic products in the European Pharmacopoeia: have all challenges been tackled?
- 作者：Mihaela Buda;Olga Kolaj-Robin;Emmanuelle Charton
- 期刊名称：《GaBi journal.》 | 2022年第1期
- Biosimilars;
- biotherapeutics;
- monographs;
- pharmacopoeia;
- public standards;
55.Development of Ph. Eur. standards for therapeutic monoclonal antibodies: infliximab case study

机译：Development of Ph. Eur. standards for therapeutic monoclonal antibodies: infliximab case study
- 作者：Mihaela Buda
- 期刊名称：《GaBi journal.》 | 2022年第3期
- Flexibility;
- infliximab;
- monographs;
- pharmacopoeia;
- public standards;
- reference preparations;
56.Substitution and interchangeability: time for a conversation?

机译：Substitution and interchangeability: time for a conversation?
- 作者：Chad Rieger;Lisa Hall;David Lim
- 期刊名称：《GaBi journal.》 | 2022年第2期
- Australia;
- interchangeable;
- substitution;
57.US prescribes' attitudes and perceptions about biosimilars

机译：US prescribes' attitudes and perceptions about biosimilars
- 作者：Michael SReilly;Ralph DMcKibbin
- 期刊名称：《GaBi journal.》 | 2022年第3期
- Biosimilars;
- interchangeable;
- prescribers;
- survey;
58.Social trust and regional variation in the adoption of biosimilars in Italy and Germany

机译：Social trust and regional variation in the adoption of biosimilars in Italy and Germany
- 作者：James C Robinson
- 期刊名称：《GaBi journal.》 | 2022年第3期
- Biosimilars;
- drug prices;
- Germany;
- healthcare costs;
- Italy;
- political trust;
- social trust;
59.Front-loading biosimilar development with analytical characterization

机译：Front-loading biosimilar development with analytical characterization
- 期刊名称：《GaBi journal.》 | 2022年第2期
- Analytics;
- biosimilars;
- functional testing;
- orthogonality;
- structural characterization;
60.On statistical evaluation for interchangeability of biosimilar products

机译：On statistical evaluation for interchangeability of biosimilar products
- 作者：Yuqi Li;Shein-Chung Chow
- 期刊名称：《GaBi journal.》 | 2022年第2期
- Biosimilar products;
- interchangeability;
- statistical evaluation;
- logarithmic transformation;
61.Key factors for successful uptake of biosimilars: Europe and the US

机译：Key factors for successful uptake of biosimilars: Europe and the US
- 作者：Michael SReilly;Professor Philip J Schneider
- 期刊名称：《GaBi journal.》 | 2022年第3期
- Biosimilars;
- health policy;
- prescribing;
- physicians;
- uptake;
62.First 2022 GaBI Journal issue highlights

机译：First 2022 GaBI Journal issue highlights
- 作者：Philip D Walson
- 期刊名称：《GaBi journal.》 | 2022年第1期
63.First GCC stakeholder meeting on approval process, interchange-ability/substitution and safety of biosimilars 2017 - Report
- 作者：Gianluca Trifiro;Meteb AI-Foheidi;AlhomaidanAhmed HAI-jedaiMusaed Abdullah AlkholiefMohammad A AlsenaidyAws AlshamsanTore Kristian Men
- 期刊名称：《GaBi journal.》 | 2018年第4期
- Biologicals;
- biosimilars;
- GCC;
- interchangeability;
- regulatory;
- Saudi Arabia;
64.First Latin American educational workshop on similar biothera-peutic products, Mexico City, Mexico, 20 January 2015
- 作者：D Walson;Robin Thorpe
- 期刊名称：《GaBi journal.》 | 2015年第3期
- Biologicals;
- biosimilars;
- follow-on drugs;
- Latin America;
- Mexico;
- regulatory practice;
65.Waiver of consent for retrospective chart review studies
- 作者：D Walson
- 期刊名称：《GaBi journal.》 | 2016年第1期
- Chart review;
- consent;
- retrospective;
- waiver;
66.First biosimilar of infliximab approved in Brazil: response from the Brazilian IBD society
- 作者：Fobio VTeixeira
- 期刊名称：《GaBi journal.》 | 2016年第1期
- Biosimilar;
- CT-P13;
- infliximab;
- inflammatory bowel disease;
67.Views of physicians and patients with chronic conditions on generic medicines in Greece after the introduction of measures to promote their consumption: findings from a qualitative study
- 作者：Eleftheria Karampli;Efstathia Triga;Vosiliki TsiantouKostos AthanasakisJohn Kyriopoulos
- 期刊名称：《GaBi journal.》 | 2016年第1期
- Generics;
- medicines consumption;
- patients;
- pharmaceutical policy;
- physicians;
- prescribing;
68.Low-cost generic drug programs in the US: implications for payers and researchers
- 作者：Joshua D Brown
- 期刊名称：《GaBi journal.》 | 2016年第1期
- Generic medications;
- low-cost generic drug programs;
- quality assessment;
- United States healthcare system;
69.Life begins at forty - hybridomas: ageing technology holds promise for future drug discoveries
- 作者：Tim Steele
- 期刊名称：《GaBi journal.》 | 2016年第1期
- Hybridomas;
- microfiuidics;
- monoclonal antibodies;
70.Pricing of biosimilars in Saudi Arabia
- 作者：Ali M Alhomaidan;Ibrahim A Aljuffali;Nasseruddeen A AL-Hoaimel
- 期刊名称：《GaBi journal.》 | 2016年第1期
- Biosimilar;
- price;
- Saudi Arabia;
71.Safety assessment of biosimilars in Europe: a regulatory perspective
- 作者：Thijs J Giezen;Christian K Schneider
- 期刊名称：《GaBi journal.》 | 2014年第4期
- Biosimilar;
- clinical safety;
- immunogenicity;
- pharmacovigilance;
72.Biosimilars versus 'biobetters'-a regulator's perspective
- 作者：Rene Anou
- 期刊名称：《GaBi journal.》 | 2014年第4期
73.Fourth and final issue of GaBI Journal's third volume
- 作者：D Walson
- 期刊名称：《GaBi journal.》 | 2014年第4期
74.Availability and procurement of generics in hospitals among medium-sized European countries
- 作者：Brian Godman
- 期刊名称：《GaBi journal.》 | 2014年第4期
75.Availability and procurement conditions of originator and generic medicines in hospitals - an exploratory study in five medium-sized European countries
- 作者：Sabine Vogler;Nina Zimmermann;Jan Mazag
- 期刊名称：《GaBi journal.》 | 2014年第4期
- Cardiovascular medicines;
- discounts;
- generics;
- procurement;
- rebates;
- tendering;
76.Access to alternative biopharma-ceuticals in low- and middle-income countries
- 作者：Abdol Majid Cheraghali
- 期刊名称：《GaBi journal.》 | 2014年第4期
77.Is Australia positioned to take advantage of biosimilars?
- 作者：David Lim
- 期刊名称：《GaBi journal.》 | 2014年第4期
- Australia;
- biosimilars;
- confidential information;
- patent;
- regulation;
- remuneration;
78.Amgen's move into the biosimilars market
- 期刊名称：《GaBi journal.》 | 2014年第4期
79.Next generation processing of monoclonal antibodies
- 作者：Jennifer Campbell;Christopher Gillespie;Michael Phillips
- 期刊名称：《GaBi journal.》 | 2017年第1期
80.Rationalizing FDA guidance on biosimilars-expediting approvals and acceptance
- 作者：Sarfaraz K Niazi
- 期刊名称：《GaBi journal.》 | 2018年第2期
- Analytical similarity;
- biosimilars;
- immunogenicity testing;
- pharmacokinetic profiling;
81.Generics authorization - groundbreaking regulatory approach to closer international cooperation on the rise - IGDRP
- 作者：Christoph Baumgartel;Katharina Gazda-Pleban
- 期刊名称：《GaBi journal.》 | 2015年第1期
82.Health Canada's perspective on the clinical development of biosimilars and related scientific and regulatory challenges
- 作者：Ally Pert;Agnes V Klein;Jian Wang
- 期刊名称：《GaBi journal.》 | 2015年第1期
- Biologicals;
- biosimilars;
- clinical trials;
- extrapolation;
- immunogenicity;
- regulatory;
83.The refinement of the super generic concept-semantic challenge for product re-innovation?
- 作者：Fereshteh Borei;Malcolm Ross
- 期刊名称：《GaBi journal.》 | 2015年第1期
- 505(b)(2) approvals;
- generics;
- improved therapeutics;
- innovation;
- new therapeutics entities;
- super generic;
84.Biosimilars: patient and physician acceptability is the fifth hurdle to market competition
- 作者：Alan Lyles
- 期刊名称：《GaBi journal.》 | 2015年第1期
- Acceptability;
- biologicals;
- biosimilars;
- interchangeability;
- pricing;
85.Editor's introduction to the initial issue of the fourth volume of GaBI Journal
- 作者：Philip D Walson
- 期刊名称：《GaBi journal.》 | 2015年第1期
86.Payer and physician evidence and discount require ments for biosimilars in three Latin American countries
- 作者：Erik Sorff;Andre Vidal Pinheiro;Daniele Severi BruniRonald J HalbertValderilio Feijo Azevedo
- 期刊名称：《GaBi journal.》 | 2015年第1期
- Biosimilar Pharmaceuticals;
- discounts;
- drug industry;
- Latin America;
- prescribing;
87.Subsequent entry biologics (biosimilars) in Canada: approaches to interchangeability and the extrapolation of indications and uses
- 作者：Agnes V Klein;Jian Wang;Patrick Bedford
- 期刊名称：《GaBi journal.》 | 2014年第3期
- Biosimilar;
- Canada;
- reference biological product;
- subsequent entry biological (SEB);
88.Barriers to market uptake of biosimilars in the US
- 作者：Joshua P Cohen;Abigail E Felix;Kim RiggsAnumeha Gupta
- 期刊名称：《GaBi journal.》 | 2014年第3期
- Biosimilar;
- interchangeability;
- originator biological;
- payer formulary;
- price discount;
- therapeutic switching;
89.Ongoing initiatives to improve prescribing efficiency in China; statins as a case history
- 作者：Wenjie Zeng;Houmei XP;Brian GodmanAlexer EFinlayson
- 期刊名称：《GaBi journal.》 | 2014年第3期
- China;
- drug utilization study;
- generics;
- health policies;
- Pharmaceuticals;
- prices;
- statins;
90.The EU regulatory approach to generics and biosimilars is essentially similar
- 作者：R Martijn van der Plos;Peter MJM Jongen;Barbara J van Zwieten-BootMarcel HN Hoefnagel
- 期刊名称：《GaBi journal.》 | 2015年第1期
- Active substance;
- biosimilar;
- EMA;
- Europe;
- guidelines;
- regulatory;
91.Where does the value of value-added'pharmaeeu ticals come from?
- 作者：Fereshteh Barei
- 期刊名称：《GaBi journal.》 | 2016年第4期
92.Retrospective chart review: disrupted anaemia control in haemodialysis patients following the switch to an iron sucrose similar (ISS) after long-term treatment with the originator iron sucrose (IS)
- 作者：Jacques Rottembourg;Corinne Emery;Alessra Moglia
- 期刊名称：《GaBi journal.》 | 2014年第3期
- Anaemia;
- cost;
- haemodialysis;
- interchangeability;
- iron sucrose;
- iron sucrose similar;
- non-biological complex drug (NBCD);
- oxidative stress;
93.GnRH agonists and antagonists in prostate cancer
- 作者：Robert Janknegt;Niels Boone;Frans ErdkampVictor Zambon
- 期刊名称：《GaBi journal.》 | 2014年第3期
94.Regional regulatory processes for the approval of biosimilars; differences and similarities
- 作者：Robin Thorpe
- 期刊名称：《GaBi journal.》 | 2014年第3期
- Biosimilars;
- follow-on products;
- Latin America;
- regulatory processes;
95.Quality standards for biopharmaceu-ticals: the importance of good manufacturing practice
- 作者：Elwyn Griffiths
- 期刊名称：《GaBi journal.》 | 2020年第3期
- ASEAN;
- biologicals;
- biosimilars;
- GMP;
- regulatory harmonization;
96.Pharmaceutical pricing in Croatia: a comparison of ordinances in 2013 versus 2009 and their potential savings to provide future guidance
- 作者：Ljiljana Sovic Brkicic;Brian Godman;Martina BogufMiron SrsenHye-YoungmWinnie de BruynTonko Tabain
- 期刊名称：《GaBi journal.》 | 2015年第2期
- Biosimilars;
- Croatia;
- generics;
- Pharmaceuticals;
- reference pricing;
- reforms;
97.Sourcing innovator products in the age of biosimilar research
- 作者：Michael Cohen
- 期刊名称：《GaBi journal.》 | 2015年第2期
- Innovator drug sourcing challenges;
98.Product naming, pricing, and market uptake of biosimilars
- 作者：Joseph PFuhr;Amitabh Chra;John RomleyTiffany ShihSuepattra G MayJacqueline Verpuye-Orgle
- 期刊名称：《GaBi journal.》 | 2015年第2期
- Biosimilar;
- market uptake;
- nomenclature;
- pricing;
- regulatory issues;
- specialty Pharmaceuticals;
99.Differences in pharmacokinetic behaviour of branded enoxaparin and a US generic version in a non-human primate model
- 作者：Professor Walter P Jeske;Jeanine M Walenga;Nicolas SimonDebra HoppensteadtJosephine CunananVicki EscalanteJawed FareedMamdouh Bakhos
- 期刊名称：《GaBi journal.》 | 2015年第2期
- Anticoagulation;
- generic;
- heparins;
- pharmacodynamics;
- pharmacokinetics;
- population;
100.First ASEAN educational workshop on regulation and approval of biosimilars/similar biothera-peutic products 2017 - Report
- 作者：Robin Thorpe;Elwyn Griffiths;Niklas Ekman
- 期刊名称：《GaBi journal.》 | 2018年第3期
- ASEAN;
- biologicals;
- biosimilars;
- education;
- regulatory;
- similar biotherapeutic product;

客服邮箱：kefu@zhangqiaokeyan.com

客服微信
服务号